Please login to the form below

Not currently logged in
Email:
Password:

Xalkori

This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

At the planned interim analysis, Lorbrena came out on top, demonstrating a significantly improved progression-free survival rate compared to Xalkori. ... Currently, Lorbrena is approved only in the second-line setting, for patients who have already been

Latest news

  • Pfizer’s Talzenna cleared for breast cancer in Europe Pfizer’s Talzenna cleared for breast cancer in Europe

    Talzenna is one of four new targeted therapies it is hoping will drive growth in cancer, along with Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC, SMO inhibitor ... The latest approval is another pillar in its bid to rebuild

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    For Pfizer, the Vizimpro approval is another pillar in its bid to rebuild its oncology franchise that has been hit hard by competition to Xalkori (crizotinib) for ALK-positive NSCLC from ... Last November, the drugmaker claimed FDA approval for Xalkori

  • Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

    It will compete in first-line ROS1-positive NSCLC against Pfizer’s Xalkori (crizotinib), which is the standard-of-care in this setting and according to some analysts it is this

  • Pfizer claims rapid FDA nod for Lorbrena Pfizer claims rapid FDA nod for Lorbrena

    Xalkori, the first ALK inhibitor drug, launched in 2011. ... Xalkori has, however, seen sales dwindle due to competition from newer drugs such as Novartis’ Zykadia and Takeda’s Alunbrig.

More from news
Approximately 22 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement

  • Who tops the pharma list? Who tops the pharma list?

    Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics